PR Newswire PharmaOriginal article
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
RegulatoryBlue Light Cystoscopy SystemsPositive
AI Analysis
Summary
Photocure announced that the FDA has published a proposed order to reclassify its Blue Light Cystoscopy Systems from Class III to Class II, potentially streamlining the regulatory pathway for the bladder cancer diagnostic device.
Outcome Details
FDA published proposed order to initiate reclassification from Class III to Class II
Importance:6/10
Sentiment:
0.70
FDAregulatoryreclassificationmedical devicebladder cancer
Related Companies
Read the original article
Published by PR Newswire Pharma on August 14, 2026 4:22 PM